- Home
- HBNC vs KURA Comparison
HBNC vs KURA Comparison
Compare HBNC & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBNC | KURA |
|---|---|---|
| Founded | 1873 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 962.4M | 841.6M |
| IPO Year | 1995 | 2015 |
Fundamental Metrics
Financial Performance| Metric | HBNC | KURA |
|---|---|---|
| Price | $19.78 | $11.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $21.00 | ★ $25.56 |
| AVG Volume (30 Days) | 833.8K | ★ 1.8M |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | N/A | $28.28 |
| Revenue Next Year | $5.52 | $106.37 |
| P/E Ratio | $38.78 | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $14.84 | $5.45 |
| 52 Week High | $20.51 | $12.49 |
Technical Indicators
Market Signals| Indicator | HBNC | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 56.30 | 66.74 |
| Support Level | $17.18 | $8.72 |
| Resistance Level | $19.93 | $11.29 |
| Average True Range (ATR) | 0.45 | 0.48 |
| MACD | 0.02 | 0.14 |
| Stochastic Oscillator | 59.83 | 95.76 |
Price Performance
Historical ComparisonAbout HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.